Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the Claims:

What is claimed is:

1. (Currently amended) A compound of formula (I):



(I)

wherein:
R^1 represents a group selected from:


, 
,


, 
, or


;

each ring of which optionally ~~contains~~ includes a further heteroatom N,
Z represents an optional substituent halogen,
alk represents alkylene or alkenylene,
T represents S, O or NH;

R^2 represents $-C_{1-6}$alkyl, $-C_{1-3}$alkylCN, $-C_{0-3}$alkylR^c, $-C_{1-3}$alkylR^f, $-C_{2-3}$alkylNR^aR^b, $-C_{2-3}$alkylOC_{1-6}alkyl, $-C_{2-3}$alkylOC_{1-3}alkyl$CONR^aR^b$, with the proviso that R^2 does not represent C_{2-3}alkylmorpholino;

R^a and R^b independently represent hydrogen, $-C_{1-6}$alkyl, or together with the N atom to which they are bonded form a 5-, 6- or 7- membered non-aromatic heterocyclic ring optionally ~~containing~~ consisting of an additional heteroatom selected from O, N or $S(O)_n$, optionally substituted by $-C_{1-4}$alkyl~~, and optionally the S heteroatom is substituted by O i.e. represents $S(O)_n$~~;

R^c represents $-C_{3-6}$cycloalkyl;

R^f represents phenyl or a 5- or 6- membered aromatic heterocyclic ring, containing at least one heteroatom selected from O, $N(O)_m$ or $S(O)_n$, optionally substituted by 0 to 2 groups selected from $-C_{1-4}$alkyl or $-NH_2$, ~~and optionally the S or N heteroatom is substituted by O, i.e. represents $S(O)_n$ or N-oxide~~;

n represents 0-2;

m represents 0 or 1;

X represents phenyl or a 5- or 6- membered aromatic heterocyclic group containing at least one heteroatom selected from O, N or S, each of which is optionally substituted by 0-2 groups selected from: halogen, $-C_{1-4}$alkyl, $-C_{2-4}$alkenyl, -CN, $-CF_3$, $-NR^aR^b$, $-C_{0-4}$alkylOR^e, $-C(O)R^d$ and $-C(O)NR^aR^b$;

R^e represents hydrogen or $-C_{1-6}$alkyl;

Y represents a substituent selected from hydrogen, halogen, $-C_{1-4}$alkyl, $-C_{2-4}$alkenyl, $-NR^aR^b$, $-NO_2$, $-C(O)NR^aR^b$, $-N(C_{1-4}$alkyl$)(CHO)$, $-NHCOC_{1-4}$alkyl, $-NHSO_2R^d$, $-C_{0-4}$alkylOR^e, $-C(O)R^d$, $-S(O)_nR^d$, or $-S(O)_2NR^aR^b$;

R^d represents $-C_{1-6}$alkyl;
~~and/~~or a pharmaceutically acceptable derivative thereof.

2. (Currently amended) A compound according to claim 1 wherein R^1 represents a group selected from:







each ring of which optionally ~~contains~~ includes a further heteroatom N,
Z represents an optional substituent halogen,
alk represents alkylene or alkenylene, and
T represents S, O or NH.
~~and/or pharmaceutically acceptable derivative thereof.~~

3. (Currently amended) A compound according to claim 1 ~~or claim 2~~ wherein R^2 represents $-C_{1-6}$alkyl, $-C_{0-3}$alkylR^c, C_{1-3}alkylR^f, $-C_{2-3}$alkylNR^aR^b, $-C_{2-3}$alkylOC_{1-6}alkyl, or $-C_{2-3}$alkylOC_{1-3}alkyl$CONR^aR^b$ ~~and/or pharmaceutically acceptable derivative thereof~~.

4. (Currently amended) A compound according to ~~any one of~~ claims ~~1-3~~ wherein X represents phenyl or a 5 or 6 membered aromatic heterocyclic group ~~containing~~ consisting of at least one heteroatom selected from O, N or S, each of which is optionally substituted by 0-2 groups selected from: halogen, $-C_{1-4}$alkyl or $-NR^aR^b$.

5. (Currently amended) A compound according to ~~any one of~~ claims ~~1-4~~ wherein Y represents a substituent selected from $-C(O)NR^aR^b$, $-S(O)_nR^d$, $-S(O)_2NR^aR^b$, $-N(C_{1-4}$alkyl$)(CHO)$ or $-NHSO_2R^d$ ~~and/or pharmaceutically acceptable derivative thereof~~.

6. (Currently amended) A compound ~~according to claim 1~~ selected from:
4-{(3*S*)-3-[{[(1*E*)-2-(5-Chloro-2-thienyl)-1-propen-1-yl]sulfonyl}(cyclopropylmethyl)amino]-2-oxo-1-pyrrolidinyl}-3-fluoro-*N*,*N*-dimethylbenzamide;
4-((3*S*)-3-{{[(1*E*)-2-(5-Chloro-2-thienyl)-1-propen-1-yl]sulfonyl}[3-(dimethylamino)propyl]amino}-2-oxo-1-pyrrolidinyl)-3-fluoro-*N*,*N*-dimethylbenzamide;
4-((3*S*)-3-{{[(1*E*)-2-(5-Chloro-2-thienyl)-1-propen-1-yl]sulfonyl}[2-(dimethylamino)ethyl]amino}-2-oxo-1-pyrrolidinyl)-3-fluoro-*N*,*N*-dimethylbenzamide;

4-[(3*S*)-3-({2-[(2-Amino-2-oxoethyl)oxy]ethyl}{[(1*E*)-2-(5-chloro-2-thienyl)-1-propen-1-yl]sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-*N,N*-dimethylbenzamide;
4-{(3*S*)-3-[{[(1*E*)-2-(5-Chloro-2-thienyl)-1-propen-1-yl]sulfonyl}(cyclopentyl)amino]-2-oxo-1-pyrrolidinyl}-3-fluoro-*N,N*-dimethylbenzamide;
4-((3*S*)-3-{{[(1*E*)-2-(5-Chloro-2-thienyl)-1-propen-1-yl]sulfonyl}[(1-methyl-1H-imidazol-2-yl)methyl]amino}-2-oxo-1-pyrrolidinyl)-3-fluoro-*N,N*-dimethylbenzamide;
4-{(3*S*)-3-[{[(1*E*)-2-(5-Chloro-2-thienyl)-1-propen-1-yl]sulfonyl}(1-methylethyl)amino]-2-oxo-1-pyrrolidinyl}-3-fluoro-*N,N*-dimethylbenzamide;
4-{(3*S*)-3-[{[(1*E*)-2-(5-Chloro-2-thienyl)-1-propen-1-yl]sulfonyl}(2-pyridinylmethyl)amino]-2-oxo-1-pyrrolidinyl}-3-fluoro-*N,N*-dimethylbenzamide;
4-((3*S*)-3-{{[(1*E*)-2-(5-Chloro-2-thienyl)-1-propen-1-yl]sulfonyl}[(3,5-dimethyl-4-isoxazolyl)methyl]amino}-2-oxo-1-pyrrolidinyl)-3-fluoro-*N,N*-dimethylbenzamide;
4-((3*S*)-3-{{[(1*E*)-2-(5-Chloro-2-thienyl)-1-propen-1-yl]sulfonyl}[2-(methyloxy)ethyl]amino}-2-oxo-1-pyrrolidinyl)-3-fluoro-*N,N*-dimethylbenzamide;
4-[(3*S*)-3-({[(1*E*)-2-(5-Chloro-2-thienyl)-1-propen-1-yl]sulfonyl}{2-[(1,1-dimethylethyl)oxy]ethyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-*N,N*-dimethylbenzamide;
4-[(3*S*)-3-([(3-Amino-2-pyrazinyl)methyl]{[(1*E*)-2-(5-chloro-2-thienyl)-1-propen-1-yl]sulfonyl}amino)-2-oxo-1-pyrrolidinyl]-3-fluoro-*N,N*-dimethylbenzamide;
4-{(3*S*)-3-[{[(1*E*)-2-(5-Chloro-2-thienyl)-1-propen-1-yl]sulfonyl}(methyl)amino]-2-oxo-1-pyrrolidinyl}-3-fluoro-*N,N*-dimethylbenzamide; and
4-{(3*S*)-3-[{[(*E*)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl}(methyl)amino]-2-oxo-1-pyrrolidinyl}-3-fluoro-*N,N*-dimethylbenzamide;
~~and/~~or a pharmaceutically acceptable derivative thereof.

7. Cancelled.

8. (Currently amended) A pharmaceutical composition comprising a compound according to ~~any one of~~ claims 1~~-6 and/or pharmaceutically acceptable derivative thereof~~ together with at least one pharmaceutical carrier ~~and/~~or excipient.

9. Cancelled.

10. (Currently amended) A method of treating a patient suffering from a condition susceptible to amelioration by a Factor Xa inhibitor comprising administering a therapeutically effective amount of a compound according to ~~any one of~~ claims 1~~-6 and/or pharmaceutically acceptable derivative thereof~~.

11. (Original) A process for preparing a compound of formula (I) which comprises reacting a compound of formula (II) with a compound of formula (III):



(II)

R^2—T (III)

where R^2 is -C_{1-6}alkyl, -C_{1-3}alkylCN, -C_{0-3}alkylR^c, -C_{1-3}alkylR^f, -C_{2-3}alkylNR^aR^b, -C_{2-3}alkylOC_{1-6}alkyl, -C_{2-3}alkylOC_{1-3}alkyl$CONR^aR^b$, with the proviso that R^2 does not represent C_{2-3}alkylmorpholino, and T is a suitable leaving group.